The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Recent advances in acute myeloid leukemia (AML) biology and its genetic landscape
should ultimately lead to more subset-specific AML therapies, ideally tailored to each …

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults
and accounts for the largest number of annual deaths due to leukemias in the United States …

Purpose Treatment outcomes in younger patients with acute myeloid leukemia (AML) have
improved, but optimization and new combinations are needed. We assess three …

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …

Modifying induction therapy in acute myeloid leukemia (AML) may improve the remission
rate and reduce the risk of relapse, thereby improving survival. Escalation of the …

Introduction: Acute myeloid leukemia (AML) is the most common acute forms of leukemia in
adults. It has a poor long-term survival with a high relapse rate and at relapse, is commonly …

Recent years have highlighted significant progress in understanding the underlying genetic
and epigenetic signatures of acute myeloid leukemia (AML). Most importantly, novel …

Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous disease.
Despite advances in understanding the pathogenesis of AML, the standard therapy …

Introduction: Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a
monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin …